Drug survival rates and reasons for drug discontinuation in patients with atopic dermatitis: a retrospective study of adult outpatients

2021 ◽  
Vol 31 (2) ◽  
pp. 233-238
Author(s):  
Jehane Pino Lopez ◽  
Christian Kromer ◽  
Raphael Herr ◽  
Astrid Schmieder ◽  
Christiane Bayerl ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Retrospective Study ◽  
Survival Rates ◽  
Drug Discontinuation ◽  
Drug Survival

scholarly journals Two-year efficacy, safety, and drug survival of dupilumab for atopic dermatitis: A real-world Canadian multicenter retrospective study

2021 ◽  
Vol 4 ◽  
pp. 67-69
Author(s):  
Jorge R. Georgakopoulos ◽  
Tina Felfeli ◽  
Aaron M. Drucker ◽  
Christine E. Jo ◽  
Vincent Piguet ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Retrospective Study ◽  
Real World ◽  
Drug Survival

scholarly journals Biologic Drug Survival in Psoriasis: A Systematic Review & Comparative Meta-Analysis

2020 ◽  
Author(s):  
Ahmed I Mourad ◽  
Robert Gniadecki
Keyword(s):  
Real World ◽  
Survival Data ◽  
Clinical Decision Making ◽  
Meta Analysis ◽  
Survival Rates ◽  
Clinical Decision ◽  
Drug Discontinuation ◽  
Large Variability ◽  
Drug Survival ◽  
Biologic Drug

Background: Drug survival studies have been utilized to evaluate the real-world effectiveness of biologics used in psoriasis. However, the increasing volume of drug survival data suffers from large variability due to regional differences in drug availability, patient selection and biologic reimbursement. Objectives: To conduct a meta-analysis of biologic drug survival to determine comparative effectiveness of the biologics in a real-world setting. Methods: Studies reporting drug survival for biologic therapy in psoriasis were identified by a systematic literature search. Hazard ratio data for drug discontinuation were estimated directly from published Kaplan-Meier estimator curves at year 1, 2 and 5 of treatment and compared pairwise for the following biologics: ustekinumab, adalimumab, etanercept, infliximab, secukinumab and ixekizumab. This pooled hazard ratios were used to estimate 2- and 5- year overall drug survival rates. Results: Ustekinumab had the longest persistence at 2 years and 5 years among all biologics included in this meta-analysis. Adalimumab was superior to etanercept and infliximab at 5 years. Pooled 5-year drug survival rates for adalimumab, etanercept, and infliximab were 46.3%, 35.9% and 34.7%, respectively. 2- and 5-year data were not available for anti-IL-17 drugs, but at 1-year ustekinumab outperformed secukinumab, the latter being equal to anti-TNFs. Conclusions: Ustekinumab is characterized by longer drug survival than TNF inhibitors and IL-17 inhibitors. Estimated pooled 2- and 5- year drug survival rates may serve as a useful tool for patient communication and clinical decision-making.

Drug survival rates and reasons for drug discontinuation in psoriasis

2016 ◽  
Vol 14 (11) ◽  
pp. 1089-1099 ◽  
Author(s):  
Tobias Arnold ◽  
Marthe-Lisa Schaarschmidt ◽  
Raphael Herr ◽  
Joachim E. Fischer ◽  
Sergij Goerdt ◽  
...  
Keyword(s):  
Survival Rates ◽  
Drug Discontinuation ◽  
Drug Survival

scholarly journals Biologic Drug Survival in Psoriasis: A Systematic Review & Comparative Meta-Analysis

2021 ◽  
Vol 7 ◽  
Author(s):  
Ahmed I. Mourad ◽  
Robert Gniadecki
Keyword(s):  
Real World ◽  
Survival Data ◽  
Clinical Decision Making ◽  
Meta Analysis ◽  
Survival Rates ◽  
Clinical Decision ◽  
Drug Discontinuation ◽  
Large Variability ◽  
Drug Survival ◽  
Biologic Drug

Drug survival studies have been utilized to evaluate the real-world effectiveness of biologics used in psoriasis. However, the increasing volume of drug survival data suffers from large variability due to regional differences in drug availability, patient selection and biologic reimbursement. The objective of this study was to conduct a meta-analysis of biologic drug survival to determine comparative effectiveness of the biologics in a real-world setting. Studies reporting drug survival for biologic therapy in psoriasis were identified by a systematic literature search. Hazard ratio data for drug discontinuation were estimated directly from published Kaplan-Meier estimator curves at year 1, 2, and 5 of treatment and compared pairwise for the following biologics: ustekinumab, adalimumab, etanercept, infliximab, secukinumab, and ixekizumab. This pooled hazard ratios were used to estimate 2- and 5-year overall drug survival rates. Ustekinumab had the longest persistence at 2 and 5 years among all biologics included in this meta-analysis. Adalimumab was superior to etanercept and infliximab at 5 years. Pooled 5-year drug survival rates for adalimumab, etanercept, and infliximab were 46.3, 35.9, and 34.7%, respectively. Two- and five-year data were not available for anti-IL-17 drugs, but at 1-year ustekinumab outperformed secukinumab, the latter being equal to anti-TNFs. In conclusion, ustekinumab is characterized by longer drug survival than TNF inhibitors and IL-17 inhibitors. Estimated pooled 2- and 5-year drug survival rates may serve as a useful tool for patient communication and clinical decision-making.

scholarly journals Long-Term Drug Survival of TNF Inhibitor Therapy in RA Patients: A Systematic Review of European National Drug Registers

2013 ◽  
Vol 2013 ◽  
pp. 1-9 ◽  
Author(s):  
Anamika Arora ◽  
Anadi Mahajan ◽  
Dean Spurden ◽  
Helen Boyd ◽  
Duncan Porter
Keyword(s):  
Systematic Review ◽  
English Language ◽  
Survival Rates ◽  
Pooled Analysis ◽  
Tnf Inhibitors ◽  
Drug Discontinuation ◽  
Tnf Inhibitor ◽  
Drug Survival ◽  
Lower Drug ◽  
Underlying Mechanisms

Objective. The present systematic review of RA registry data was undertaken to analyse the time on treatment of licensed TNF inhibitors in patients with RA in Europe.Methods. English language European registry studies comparing TNF inhibitors were searched using MEDLINE, Embase, Cochrane, and WHO: ICTRP up to 16 April 2012 and proceedings of three selected conferences held between 2010 and 2012. Pooled analysis was performed to determine drug survival rates for each TNF inhibitor.Results. Sixteen studies met the inclusion criteria, of which 11 studies assessed biologic-naive patients and five studies included a mixed population of biologic-naive and biologic pretreated patients. The overall effectiveness of TNF inhibitors diminished with time, leading to decreased drug survival rates. Pooled drug survival rates after 60 months follow-up were 37% (infliximab), 48% (adalimumab), and 52% (etanercept). Further, in an observational study, when TNF inhibitors were used in combination with methotrexate, a longer drug survival was observed compared to TNF inhibitors alone.Conclusion. The findings of this systematic review indicated numerically lower drug discontinuation rates with etanercept than adalimumab, whereas infliximab had the highest rate. Further research is needed to understand the underlying mechanisms of treatment discontinuation with TNF inhibitors.

Cirurgia Paliativa em Pacientes com Tumor Periampular Irressecável: Estudo Retrospectivo de 5 Anos em um Hospital em São José dos Campos – SP/Surgical Palliation in Patients with Unresectable Periampullary Tumor: a Retrospective Study of 5 Years in a Hosp

1970 ◽  
Vol 3 (4) ◽  
pp. 9-20
Author(s):  
José Henrique Gomes Torres ◽  
Rosyane Rena De Freitas
Keyword(s):  
Pancreatic Cancer ◽  
Retrospective Study ◽  
Survival Rates ◽  
Periampullary Tumor ◽  
The Past ◽  
Palliative Procedure ◽  
Surgical Palliation ◽  
Head Of The Pancreas ◽  
Keywords Pancreatic Cancer ◽  
Main Complication

Objetivo: Avaliar diferentes métodos paliativos quanto a sua resolução, complicações e sobrevida em pacientes com tumor periampular irressecável. Materiais e métodos: Estudo retrospectivo com análise dos prontuários de pacientes com tumor periampular irressecável e que foram submetidos a procedimento paliativo no Hospital Municipal Dr José de Carvalho Florence nos últimos cinco anos. Resultados: O principal tumor periampular foi o de cabeça de pâncreas, com incidência de 94%, acometendo pacientes com média de 66 anos, sem preferência por sexo. Os procedimentos mais realizados foram derivação biliar e colocação de endoprótese através de colangiopancreatografia endoscópica retrógrada, apresentando sobrevidas de 586 e 56 dias, respectivamente. Conclusão: A coledocojejunostomia foi o procedimento mais realizado e apresentou menor tempo de internação e maiores sobrevida e tempo de permanência anictérico. Pneumonia foi a complicação mais frequente.  Palavras chave: Câncer pancreático, Colangiocarcinoma, Cuidados paliativos.  Objective: To evaluate different palliative methods concerning its resolution, complications and survival in patients with unresectable periampular tumor. Materials and methods: Retrospective study analysing records of patients with unresectable periampullary tumor and who underwent palliative procedure in the Hospital Municipal Dr José de Carvalho Florence in the past five years. Results: The main periampullary tumor was the head of the pancreas, with an incidence of 94%, affecting patients with an average of 66 years old, regardless of gender. The most common procedures were bypass and biliary stent, with survival rates of 586 and 56 days, respectively. Conclusion: Coledocojejunostomy was the procedure which was the most often performed and showed a shorter hospital stay and longer survival time and time without jaundice. Pneumonia was the main complication.  Keywords: Pancreatic cancer, Cholangiocarcinoma, Palliative care  

Efficacy, safety and Drug Survival of IL-23, IL-17 and TNF-alpha Inhibitors for Psoriasis Treatment: A Retrospective Study

2021 ◽  
pp. 1-20
Author(s):  
Paolo Dapavo ◽  
Niccolò Siliquini ◽  
Luca Mastorino ◽  
Gianluca Avallone ◽  
Martina Merli ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Tnf Alpha ◽  
Psoriasis Treatment ◽  
Drug Survival
Sign in / Sign up

Export Citation Format

Share Document